Tomographie par émission de positons et fusion d'images de simulation virtuelle par tomodensitométrie. Impact sur la planification de la radiothérapie conformationnelle des cancers de l'œsophage

Moureau-Zabotto, Laurence; Touboul, E.; Lerouge, D.; Deniaud-Alexandre, É.; Grahek, D.; Foulquier, J.N.; Petenief, Y.; Grès, B. Du; Balaa, Hanna El; Kerrou, K.; Montravers, F.; Keraudy, K.; Tiret, Emmanuel; Gendre, Jean–Pierre; Grangé, Jean‐Didier; Hourry, S.; Talbot, Jean-Noël

doi:10.1016/j.canrad.2005.04.001

Cited by 8 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of FDG-PET/CT has been shown to change target volumes contoured by radiation oncologists in a considerable proportion of patients (20–90%) with consequent changes in treatment planning (38, 39). The tumor length evaluated by FDG-PET at an SUV cut off of 2.5 seemed most approximate to the pathological tumor length (40, 41).…”

Section: Esophageal Cancersmentioning

confidence: 99%

Application of Metabolic PET Imaging in Radiation Oncology

et al. 2012

View full text Add to dashboard Cite

Positron emission tomography (PET) is a noninvasive imaging technique that provides functional or metabolic assessment of normal tissue or disease conditions and is playing an increasing role in cancer radiotherapy planning. 18F-fluorodeoxyglucose PET imaging (FDG-PET) is widely used in the clinic for tumor imaging due to increased glucose metabolism in most type of tumors; its role in radiotherapy management of various cancers is reviewed. In addition, other metabolic PET imaging agents at various stages of preclinical and clinical development are reviewed. These agents include radiolabeled amino acids such as methionine for detecting increased protein synthesis, radiolabeled choline for detecting increased membrane lipid synthesis, and radiolabeled acetate for detecting increased cytoplasmic lipid synthesis. The amino acid analogs choline and acetate are often more specific to tumor cells than FDG, so they may play an important role in differentiating cancers from benign conditions and in the diagnosis of cancers with either low FDG uptake or high background FDG uptake. PET imaging with FDG and other metabolic PET imaging agents is playing an increasing role in complementary radiotherapy planning.

show abstract